bluebird bio, Inc. (NASDAQ:BLUE) – Wedbush decreased their FY2017 EPS estimates for bluebird bio in a report issued on Monday. Wedbush analyst D. Nierengarten now anticipates that the biotechnology company will post earnings per share of ($7.27) for the year, down from their prior forecast of ($6.90). Wedbush has a “Outperform” rating and a $174.00 price objective on the stock. Wedbush also issued estimates for bluebird bio’s Q4 2017 earnings at ($2.10) EPS, FY2018 earnings at ($6.83) EPS, FY2019 earnings at ($7.05) EPS, FY2020 earnings at ($4.33) EPS and FY2021 earnings at $6.30 EPS.
bluebird bio (NASDAQ:BLUE) last released its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.68) by ($0.05). The firm had revenue of $7.71 million for the quarter, compared to analysts’ expectations of $8.47 million. bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The firm’s quarterly revenue was up 397.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($2.07) EPS.
Shares of bluebird bio (NASDAQ BLUE) opened at $184.90 on Thursday. bluebird bio has a 12-month low of $60.95 and a 12-month high of $222.03.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC raised its holdings in shares of bluebird bio by 9.6% in the second quarter. FMR LLC now owns 6,713,949 shares of the biotechnology company’s stock valued at $705,301,000 after buying an additional 587,236 shares during the last quarter. Capital Research Global Investors raised its holdings in shares of bluebird bio by 9.9% in the second quarter. Capital Research Global Investors now owns 5,483,117 shares of the biotechnology company’s stock valued at $576,001,000 after buying an additional 493,072 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of bluebird bio by 10.7% in the second quarter. Vanguard Group Inc. now owns 3,559,102 shares of the biotechnology company’s stock valued at $373,884,000 after buying an additional 343,856 shares during the last quarter. Eagle Asset Management Inc. purchased a new stake in shares of bluebird bio in the third quarter valued at about $29,539,000. Finally, American Century Companies Inc. purchased a new stake in shares of bluebird bio in the third quarter valued at about $31,170,000.
In related news, insider Jeffrey T. Walsh sold 4,900 shares of the business’s stock in a transaction on Tuesday, October 10th. The shares were sold at an average price of $129.94, for a total value of $636,706.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David Davidson sold 4,000 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $131.31, for a total transaction of $525,240.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 97,582 shares of company stock valued at $15,597,932. 3.90% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: “FY2017 EPS Estimates for bluebird bio, Inc. Lowered by Wedbush (BLUE)” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/12/14/fy2017-eps-estimates-for-bluebird-bio-inc-lowered-by-wedbush-blue.html.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.